In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).
![](https://www.inmedpharma.com/wp-content/uploads/2024/07/InMed_INM-089-Article-Investor-Wire-768x398.png)
Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development